Research Article
Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry
Table 2
Clinical outcomes during hospitalization after propensity score matching.
| | | Patients without prior OAC (N = 638) | Patients with prior OAC (N = 638) | OR (95% CI) | value | | N (%) | Incidence per 100 patients-days (95% CI) | N (%) | Incidence per 100 patients-days (95% CI) |
| | Intensive care unit admission | 40 (6.3) | 0.52 (0.37–0.71) | 44 (6.9) | 0.58 (0.42–0.77) | 1.11 (0.71–1.73) | 0.652 | | Renal failure | 151 (23.7) | 1.97 (1.67–2.31) | 212 (33.2) | 2.77 (2.41–3.17) | 1.61 (1.26–2.06) | 0.001 | | Respiratory insufficiency | 413 (64.7) | 5.39 (4.89–5.94) | 429 (67.2) | 5.60 (5.09–6.16) | 1.09 (0.86–1.38) | 0.280 | | Upper respiratory tract infection | 90 (14.1) | 1.18 (0.95–1.44) | 89 (13.9) | 1.16 (0.93–1.43) | 0.99 (0.72–1.35) | 0.987 | | Heart failure | 65 (10.2) | 0.85 (0.66–1.08) | 115 (18.0) | 1.50 (1.24–1.80) | 1.93 (1.39–2.68) | <0.001 | | Sepsis | 77 (12.1) | 1.01 (0.79–1.26) | 96 (15.0) | 1.25 (1.02–1.53) | 1.29 (0.93–1.78) | 0.299 | | Systemic inflammatory response syndrome | 129 (20.2) | 1.69 (1.41–2.00) | 181 (28.4) | 2.36 (2.03–2.73) | 1.55 (1.20–2.02) | 0.003 | | All-cause mortality | 197 (30.9) | 2.57 (2.23–2.96) | 243 (38.1) | 3.17 (2.79–3.60) | 1.38 (1.09–1.74) | 0.007 | | Any thrombotic/thromboembolic event | 19 (3.0) | 0.25 (0.15–0.39) | 21 (3.3) | 0.27 (0.17–0.42) | 1.11 (0.59–2.08) | 0.748 | | Any clinically relevant bleeding | 26 (4.1) | 0.34 (0.22–0.50) | 73 (11.4) | 0.96 (0.75–1.20) | 3.04 (1.92–4.83) | <0.001 |
|
|
